ClinicalTrials.gg

Program

abrocitinib

Also written as “PF-04965842”, “PF-04965842 200 mg” and “PF-04965842 100 mg”.

Its studies are mostly in Dermatitis, Atopic · Dermatitis · Eczema · Renal Insufficiency · Psoriasis, led by Pfizer.

Furthest: phase 3, since Nov 17, 201730 company-led studies, 3 open or runningNext primary completion: May 2, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer303 open or runningphase 3since Nov 17, 2017Apr 15, 2013May 2, 2027phase 3 · NCT06807268

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Apr 15, 2013.

  1. Aug 8, 20183 phase 1 studiesNCT03626415, NCT03634345, NCT03637790
  2. Sep 4, 20182 phase 1 studiesNCT03660241, NCT03662516
  3. Oct 24, 2018Phase 3 study in DermatitisNCT03720470 · 838 enrolled · United States, Australia, Bulgaria and more
  4. Nov 13, 2018Phase 1 study in HealthyNCT03742336 · 20 enrolled · Belgium
  5. Jan 4, 2019Phase 3 study in Dermatitis, AtopicNCT03796676 · 287 enrolled · United States, Australia, China and more
  6. Jan 4, 20192 phase 1 studiesNCT03796182, NCT03806101
  7. Mar 22, 2019Phase 2 study in Dermatitis, AtopicNCT03915496 · 46 enrolled · United States, Canada
  8. Sep 3, 2019Phase 1 study in HEALTHYNCT04099563 · 13 enrolled · China
  9. Mar 27, 2020Phase 3 study in Dermatitis, AtopicNCT04345367 · 727 enrolled · United States, Australia, Bulgaria and more
  10. May 21, 2021Phase 1 study in Dermatitis, AtopicNCT04903093 · 19 enrolled · United States
  11. Sep 24, 2021Phase 1 study in Healthy ParticipantsNCT05067439 · 26 enrolled · United States
  12. May 11, 2022Phase 3 study in Dermatitis, AtopicNCT05375929 · 200 enrolled · India
  13. Jan 29, 20252 phase 3 studiesNCT06807281, NCT06807268
  14. Sep 11, 2026Phase 3 study in Dermatitis, AtopicNCT07823595 · 90 planned

Ahead

  1. May 2, 2027Primary completion: phase 3 study in EczemaNCT06807268
  2. Apr 10, 2029Primary completion: phase 3 study in Dermatitis, AtopicNCT07823595
  3. Feb 22, 2032Primary completion: phase 3 study in Dermatitis, AtopicNCT06807281

TargetBeta

JAK1 →read by rule
“Tyrosine-protein kinase JAK1 inhibitor”ChEMBL 37, by rule

Other programs on JAK1

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
baricitinibruleEli Lillyphase 459
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
jaktinibruleSuzhou Zelgen Biopharmaceuticalsphase 331
ivarmacitinibruleJiangsu HengRui Medicinephase 325
brepocitinibrulePfizerphase 325
delgocitinibruleLEO Pharmaphase 321
momelotinibruleGlaxoSmithKlinephase 317
golidocitinibruleDizal Pharmaceuticalsphase 310

Studies

All 30 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07823595Dermatitis, Atopic3Not yet recruitingApr 10, 202990
NCT06807281Dermatitis, Atopic · United States, China, Hungary and more3RecruitingFeb 22, 2032450
NCT06807268Eczema · United States, China, Germany and more3Active, not recruitingMay 2, 2027151
NCT05375929Dermatitis, Atopic · India3CompletedJun 9, 2023200
NCT05067439Healthy Participants · United States1CompletedFeb 26, 202226
NCT04903093Dermatitis, Atopic · United States1CompletedOct 26, 202119
NCT04345367Dermatitis, Atopic · United States, Australia, Bulgaria and more3CompletedJul 13, 2021727
NCT04099563HEALTHY · China1CompletedNov 9, 201913
NCT03915496Dermatitis, Atopic · United States, Canada2CompletedNov 16, 202146
NCT03806101Healthy · Belgium1CompletedMar 15, 201912
NCT03796676Dermatitis, Atopic · United States, Australia, China and more3CompletedApr 8, 2020287
NCT03796182Dermatitis, Atopic · Belgium1CompletedFeb 13, 201912
NCT03742336Healthy · Belgium1CompletedFeb 18, 201920
NCT03720470Dermatitis · United States, Australia, Bulgaria and more3CompletedDec 27, 2019838
NCT03662516Healthy Females · United States1CompletedJan 19, 201917
NCT03660241Renal Insufficiency · United States, Belgium1CompletedNov 5, 201923
NCT03637790Healthy · Belgium1CompletedDec 14, 201812
NCT03634345Dermatitis, Atopic · Belgium1CompletedDec 13, 201824
NCT03626415Hepatic Impairment · United States1CompletedApr 30, 201924
NCT03647670Phase 1 · Belgium1CompletedOct 16, 201825
NCT03575871Dermatitis, Atopic · United States, Australia, Bulgaria and more3CompletedAug 13, 2019391
NCT03627767Dermatitis · United States, Argentina, Belgium and more3CompletedSep 2, 20201,235
NCT03386279Healthy Volunteers · Belgium1CompletedOct 1, 201836
NCT03422822Dermatitis, Atopic · United States, Argentina, Australia and more3CompletedDec 22, 20253,166
NCT03349060Dermatitis, Atopic · United States, Australia, Canada and more3CompletedMar 26, 2019387
NCT03250039Healthy · Netherlands1CompletedSep 15, 20176
NCT02780167Dermatitis, Atopic · United States, Australia, Canada and more2CompletedMar 2017269
NCT02201524Plaque, Amyloid · United States, Canada2TerminatedSep 201559
NCT02163161Fasting · Belgium1CompletedAug 201412
NCT01835197Healthy · United States1CompletedJun 201479

How it is read

Names in the registry

  • “PF-04965842”, 26 entries
  • “PF-04965842 200 mg”, 5 entries
  • “PF-04965842 100 mg”, 5 entries
  • “Abrocitinib”, 4 entries
  • “Abrocitinib 200 mg”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.